AviadoBio Appoints Dr. David Cooper as Chief Medical Officer
• A neurosurgeon with more than 20 years’ biopharmaceutical experience and proven expertise in gene therapy and rare diseases
• Has supported multiple successful clinical development programs leading to, four BLA submissions and product launches
London, UK; Tuesday, August 2, 2022 — AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, today announced the appointment of David Cooper, MD, MBA, as Chief Medical Officer (CMO).
Dr. Cooper joins AviadoBio from uniQure, Inc where he was Vice President, Clinical Development, working to translate preclinical gene therapy assets to clinic and execute on multiple Phase I – III clinical programs. This included the pioneering first human dose studies in US and EU for intraparenchymal gene therapy for early-stage Huntington’s Disease, AMT 130. Prior to uniQure, Dr Cooper spent the majority of his industry career at Novo Nordisk within the hemophilia and rare bleeding disorders space as a key contributor to strategic clinical development planning, trial execution and life cycle management. He served as uniQure’s clinical lead on the hemophilia B gene therapy (Hemgenix) through the BLA/MAA submissions, and supported four successful BLA submissions and product launches in the hemophilia therapeutic area at Novo Nordisk.
“David brings a uniquely strong set of skills and experience to AviadoBio. He has a proven track record in the design and implementation of complex clinical development programs in gene therapy and in rare diseases. I have no doubt he will make a tremendous impact as we advance our gene therapies for frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) into the clinic,” said Lisa Deschamps, Chief Executive Officer.
Dr. Cooper commented, “As a neurosurgeon, I have sadly seen the devastating impact neurodegenerative diseases have on patients and their families. For diseases with a genetic mutation, gene therapies offer the best route to a transformative one-time treatment. I believe AviadoBio’s neuroanatomy-led approach to developing best-in-class gene therapies has the potential to overcome the critical challenges in delivering safe and effective doses of gene therapy to the central nervous system. I am very excited to be joining the Company and look forward to working to advance its candidates through clinical development and, ultimately, to transform the lives of people living with FTD and ALS.”
Dr. Cooper completed his Doctor of Medicine at Cornell University and trained as a neurosurgeon at the State University of New York Health Science Center, NY, before starting his clinical practice. He was awarded an MBA with Distinction from the Johnson Graduate School of Management, Cornell University. He is a respected expert and collaborator in the area of clinical trials and observational research and has published more than 90 publications and over 200 scientific posters and oral presentations.